Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCLK1 | O15075 | 5/20 | 0.45 |
| ▸ | BRD4 | O60885 | 10/20 | 0.41 |
| ▸ | MAPK7 | Q13164 | 9/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | PIK3C2G | O75747 | 3/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17059804 | 0.84 | MAPK7 (0.54) | DCLK1BRD4MAPK7TTRCES1 | |
| SCHEMBL25357908 | 0.79 | DCLK1 (0.52) | DCLK1BRD4MAPK7TTRCES1 | |
| SCHEMBL30526068 | 0.79 | DCLK1 (0.52) | DCLK1BRD4MAPK7TTRCES1 | |
| SCHEMBL18370115 | 0.77 | DCLK1 (0.50) | DCLK1BRD4MAPK7LRRK2PIK3CD | |
| SCHEMBL17059741 | 0.74 | BRD4 (0.78) | DCLK1BRD4MAPK7LRRK2BRDT | |
| SCHEMBL29582820 | 0.73 | DCLK1 (0.48) | DCLK1BRD4MAPK7TTRCES1 | |
| SCHEMBL17059742 | 0.71 | MAPK7 (0.57) | DCLK1BRD4MAPK7TTRCES1 | |
| SCHEMBL17059740 | 0.71 | MAPK7 (0.42) | BRD4MAPK7TTRCES1LRRK2 | |
| SCHEMBL18379111 | 0.70 | MAPK7 (0.54) | DCLK1BRD4MAPK7TTRCES1 | |
| SCHEMBL17059747 | 0.70 | MAPT (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | ACTIVX BIOSCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | ACTIVX BIOSCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| WO-2015129927-A1 | HETEROCYCLIC COMPOUNDS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | BET1, EP300, RBBP5 | DCLK1 3272/4885BRD4 4/4885MAPK7 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.